Xeris Biopharma Holdings, Inc. (XERS)
8.115
-0.08
(-0.92%)
USD |
NASDAQ |
Aug 05, 16:00
8.115
0.00 (0.00%)
After-Hours: 18:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.400B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 47.30% |
| Valuation | |
| PE Ratio | 123.89 |
| PE Ratio (Forward) | |
| PS Ratio | 4.477 |
| Price to Book Value | 107.63 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 19.87 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 96.22% |
Profile
| Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL. |
| URL | http://www.xerispharma.com |
| Investor Relations URL | https://ir.xerispharma.com/ |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Aug. 06, 2026 |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL. |
| URL | http://www.xerispharma.com |
| Investor Relations URL | https://ir.xerispharma.com/ |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Aug. 06, 2026 |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |